Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
-
Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population Data Demonstrate REM-422, the First-in-Class Small Molecule MYB mRNA Degrader, Reduces Expression of the...
-
WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
-
WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
-
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
-
WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...
-
CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying...
-
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying...
-
CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying...